for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Boston Scientific Corporation

BSX.N

Latest Trade

43.26USD

Change

0.25(+0.58%)

Volume

1,408,545

Today's Range

42.57

 - 

43.41

52 Week Range

31.57

 - 

43.83

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
43.01
Open
43.06
Volume
1,408,545
3M AVG Volume
150.10
Today's High
43.41
Today's Low
42.57
52 Week High
43.83
52 Week Low
31.57
Shares Out (MIL)
1,393.82
Market Cap (MIL)
59,390.82
Forward P/E
27.16
Dividend (Yield %)
--

Next Event

Boston Scientific Corp at Piper Jaffray Healthcare Conference

Latest Developments

More

Boston Scientific's Unit And Ontario Municipal Employees Retirement System Entered Into Royalty Purchase Agreement

Boston Scientific Prices €900 Mln Of Senior Notes

Biocardia - Filed Counterclaim In Federal Action Against Boston Scientific Parties, Surbhi Sarna

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Boston Scientific Corporation

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology. It operates in three segments: Cardiovascular, Rhythm Management and MedSurg. Its Cardiovascular segment consists of Interventional Cardiology and Peripheral Interventions businesses. Rhythm Management consists of Cardiac Rhythm Management and Electrophysiology businesses. MedSurg consists of Endoscopy, Urology and Pelvic Health, and Neuromodulation businesses. Its Interventional Cardiology product offerings include balloon catheters, rotational atherectomy systems, guide wires, guide catheters and embolic protection devices and diagnostic catheters used in percutaneous transluminal coronary angioplasty (PTCA) procedures.

Industry

Medical Equipment & Supplies

Contact Info

300 BOSTON SCIENTIFIC WAY

+1.508.6834000

https://www.bostonscientific.com/

Executive Leadership

Michael F. Mahoney

Chairman of the Board, President, Chief Executive Officer

Daniel J. Brennan

Chief Financial Officer, Executive Vice President

Kevin J. Ballinger

Executive Vice President and Global President - Interventional Cardiology

Joseph M. Fitzgerald

Executive Vice President and President - Rhythm Management

Edward F. Mackey

Executive Vice President - Operations

Key Stats

1.43 mean rating - 23 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

8.4K

2017

9.0K

2018

9.8K

2019(E)

10.8K
EPS (USD)

2016

1.110

2017

1.260

2018

1.470

2019(E)

1.569
Price To Earnings (TTM)
58.14
Price To Sales (TTM)
5.72
Price To Book (MRQ)
6.12
Price To Cash Flow (TTM)
29.73
Total Debt To Equity (MRQ)
112.25
LT Debt To Equity (MRQ)
98.88
Return on Investment (TTM)
5.46
Return on Equity (TTM)
4.38

Latest News

Latest News

Boston Scientific's narrow profit beat fails to excite investors

Boston Scientific Corp <BSX.N> narrowly beat Wall Street estimates for quarterly profit on Wednesday, helped by higher sales of its surgical products used to treat urological and pelvic conditions.

Boston Scientific profit falls 72% on acquisition charges

U.S. medical device maker Boston Scientific Corp reported a 72.3% drop in second-quarter profit on Wednesday, hit by charges related to its acquisition of Britain's BTG Plc.

Boston Scientific trims 2019 sales growth forecast on weak first quarter, shares fall

Boston Scientific Corp on Wednesday posted a rare first-quarter profit and revenue miss and lowered the top end of its 2019 sales growth forecast as the medical device maker faces regulatory scrutiny for some of its products.

Boston Scientific sees $25 million hit to 2019 revenue from mesh withdrawal

Boston Scientific Corp on Wednesday said it expects a setback of about $25 million to its full-year revenue due to the U.S. Food and Drugs Administration's order to halt sales of its transvaginal surgical mesh products.

Edward Lifesciences pays Boston Scientific $180 million to end patent row

Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement to end long-standing patent disputes between the two medical device makers.

Edward Lifesciences settles patent disputes with Boston Scientific

Edwards Lifesciences Corp has paid rival Boston Scientific Corp $180 million as part of a settlement related to all outstanding patent disputes between the companies, the medical device makers said in a joint statement on Tuesday.

Boston Scientific backs BTG offer with £3.3bn bridge loan

US medical device maker Boston Scientific is backing its recommended cash offer for UK-based BTG plc with a £3.3bn (US$4.22bn)bridge loan from Barclays Bank.

Boston Scientific backs BTG offer with £3.3bn bridge loan

US medical device maker Boston Scientific is backing its recommended cash offer for UK-based BTG plc with a £3.3bn bridge loan from Barclays Bank.

Boston Scientific builds medical technology with $4.2 billion BTG deal

U.S. medical device maker Boston Scientific Corp <BSX.N> has agreed to buy Britain's BTG Plc <BTG.L> for 3.3 billion pounds ($4.24 billion) in cash, adding technology to fight cancer and other serious diseases to its portfolio.

Boston Scientific offers to buy UK's BTG for about $4.24 billion

U.S. medical device maker Boston Scientific Corp said it offered to buy British pharmaceutical firm BTG Plc for about 3.3 billion pounds ($4.24 billion) in cash.

Surgical product sales drive Boston Scientific's profit beat

Medical device company Boston Scientific Corp <BSX.N> posted a slightly better-than-expected quarterly profit on Wednesday, helped by higher sales in its MedSurg business, which makes surgical products for various urological and pelvic disorders.

Boston Scientific posts 53 percent jump in third-quarter profit

Medical device maker Boston Scientific Corp posted a 52.7 percent jump in quarterly profit on Wednesday, helped by higher sales in its cardiovascular business, which makes stents and heart valves.

Medical device maker Stryker says not in talks to buy Boston Scientific

Medical device maker Stryker Corp <SYK.N> is not in talks to buy rival Boston Scientific Corp <BSX.N>, the company said in a regulatory filing https://bit.ly/2Jy6VQB on Wednesday, two days after a media report of a potential deal between the two surfaced.

Medical device maker Stryker says not in talks to buy Boston Scientific

Medical device maker Stryker Corp was not in discussions to buy rival Boston Scientific Corp, Stryker said in a regulatory filing https://bit.ly/2Jy6VQB on Wednesday.

Medical device maker Stryker makes takeover approach to Boston Scientific: WSJ

Medical device maker Stryker Corp has made a takeover approach to rival Boston Scientific Corp, the Wall Street Journal reported on Monday, a combination that would give Stryker a strong position in stroke-preventing heart products.

Device maker Stryker has made a takeover approach to Boston Scientific - WSJ

Device maker Stryker Corp has made a takeover approach to Boston Scientific Corp, the Wall Street Journal reported https://www.wsj.com/articles/stryker-has-made-a-takeover-approach-to-boston-scientific-1528727749?mod=searchresults&page=1&pos=1, citing sources.

BRIEF-Jana Partners LLC Takes Sole Share Stake In Allergan, Boston Scientific

* JANA PARTNERS LLC TAKES SOLE SHARE STAKE IN ALLERGAN PLC OF 12,000 SHARES - SEC FILING

BRIEF-Boston Scientific Closes NxThera Acquisition

* BOSTON SCIENTIFIC CLOSES NXTHERA ACQUISITION Source text for Eikon: Further company coverage:

Heart valve demand helps drive Boston Scientific's forecast

Boston Scientific Corp <BSX.N> raised its full-year forecast on Wednesday after reporting stronger-than-expected growth across its businesses, soothing fears that it was losing share in the lucrative market for heart valves.

BRIEF-Boston Scientific Announces Q1 GAAP Earnings Per Share $0.21

* Q1 EARNINGS PER SHARE VIEW $0.32 -- THOMSON REUTERS I/B/E/S

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up